04:37 PM EDT, 03/22/2024 (MT Newswires) -- Matthew K Fust, Director, on March 20, 2024, sold 60,000 shares in Crinetics Pharmaceuticals ( CRNX ) for $2,648,150. Following the Form 4 filing with the SEC, Fust has control over a total of 18,536 shares of the company, with 18,536 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/xslF345X03/doc4.xml